Compare Peptides

Select any two compounds for a side-by-side comparison of mechanism, uses, risks, and FDA regulatory status.

Popular comparisons

Pemvidutide

ALT-801, Altimmune dual agonist

Investigational
Metabolic & Weight Management
Full profile

Survodutide

BI 456906, Boehringer Ingelheim dual agonist

Investigational
Metabolic & Weight Management
Full profile
Overview

A GLP-1/glucagon dual receptor agonist developed by Altimmune, similar in mechanism to survodutide. In Phase 2 trials (MOMENTUM), pemvidutide demonstrated up to 15.6% weight loss at 48 weeks with notable preservation of lean body mass — a differentiating feature compared to other weight loss drugs where significant muscle loss is a concern.

A dual glucagon/GLP-1 receptor agonist developed by Boehringer Ingelheim for obesity and metabolic liver disease (MASH/NASH). Unlike tirzepatide (GIP/GLP-1), survodutide activates the glucagon receptor alongside GLP-1, which increases energy expenditure and hepatic fat oxidation. Phase 2 trials showed up to 18.7% weight loss at 46 weeks and significant liver fat reduction, making it a leading candidate for MASH treatment.

Mechanism of Action

Activates both GLP-1 and glucagon receptors. GLP-1 reduces appetite and food intake. Glucagon activation increases energy expenditure, promotes fat oxidation, and may help preserve lean mass during weight loss by shifting energy substrate utilization toward fat rather than protein catabolism.

Dual agonism of glucagon and GLP-1 receptors. GLP-1 activation reduces appetite and slows gastric emptying. Glucagon activation increases hepatic fat oxidation, energy expenditure, and thermogenesis. The combination targets both caloric intake and energy output, with particular benefit for liver fat reduction — a mechanism not shared by pure GLP-1 agonists.

Common Uses
  • Weight management (investigational)
  • MASH/NASH treatment (investigational)
  • Lean mass preservation during weight loss
  • Weight management (investigational)
  • MASH/NASH treatment (investigational)
  • Metabolic syndrome
  • Liver fat reduction
Known Risks
  • GI side effects (nausea, diarrhea)
  • Still in clinical trials — full safety profile not established
  • Potential blood sugar effects
  • Injection site reactions
  • GI side effects (nausea, vomiting, diarrhea) — common in GLP-1 class
  • Potential blood sugar effects from glucagon activation
  • Still in Phase 3 trials — full safety profile not established
  • Injection site reactions
Regulatory Status
Investigational

Phase 2 completed (MOMENTUM trial). Phase 2b for MASH (IMPACT trial) ongoing. Altimmune reported 15.6% weight loss at 48 weeks with lean mass preservation. Phase 3 planning underway. The lean mass preservation claim is a key differentiator if confirmed in larger trials.

Investigational

Currently in Phase 3 trials for obesity (SYNCHRONIZE program) and MASH (LIVERAGE program). Phase 2 data showed 18.7% weight loss at 46 weeks and 87% relative reduction in liver fat. Potential FDA submission expected 2027. Represents a differentiated mechanism from tirzepatide and semaglutide.

Research References

This comparison is for educational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional before starting any peptide therapy.

Compare Clinics →

Side-by-side pricing, peptides offered, trust scores, and patient ratings.

Compare Vendors →

Side-by-side trust scores, purity data, COA verification, and compounds.